Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flow from operating activities:
Net loss	$ (3,370,715)	$ (3,888,713)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	323,602	321,980
Vesting expense	36,518	565,082
Common stock issued for consulting and other	162,122	(4,048)
Amortization of debt discount	0	244,830
Gain on valuation of equity-linked instruments and derivative liability	(1,908)	(95,671)
Loss on fixed asset disposal	1,200	0
Changes in assets and liabilities:
Accounts receivable	89,230	(8,050)
Inventories	(67,996)	(3,289)
Prepaid expense and other assets	197,123	(55,431)
Accounts payable	85,037	(345,070)
Accrued expenses and other liabilities	(581,267)	(82,271)
Deferred revenue	(4,325)	101,167
Other long-term liabilities	37,683	(72,607)
Net cash used in operating activities:	(3,093,696)	(3,322,091)
Cash flow from investing activities:
Purchase of fixed assets	(45,399)	(391,685)
Acquisition of intangibles	(34,844)	(1,436)
Net cash used in investing activities	(80,243)	(393,121)
Cash flow from financing activities:
Proceeds from issuance of common stock and warrants, net	0	31,077,231
Proceeds from exercise of warrants into common stock	0	4,495,270
Repayment of debt	0	(4,162,744)
Payment premium	0	(1,073,470)
Proceeds from issuance of common stock pursuant to equity line	86,885	0
Net cash provided by financing activities	86,885	30,336,287
Net increase (decrease) in cash and cash equivalents	(3,087,054)	26,621,075
Cash and cash equivalents at beginning of period	28,202,615	678,332
Cash and cash equivalents at end of period	25,115,561	27,299,407
Non-cash transactions:
Shares issued to CEO per agreement related to accrued interest	0	143,573
Shares issued pursuant to convertible debt	$ 0	$ 514,011